NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

NCT07402044

Not Yet RecruitingN/A

Sponsor: Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Conditions: CABOTEGRAVIR, LENACAPAVIR

Countries: France

The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

* Age ≥18 years
* HIV-1 infection
* Patients who started taking cabotegravir combined with lenacapavir between July 2024 and the one-year follow-up, or who are due to start taking the CAB/LEN combination.
* Patients who are due to start the CAB/LEN combination following a medical decision.

Exclusion Criteria:

* Participants' objection to the use of follow-up data

Locations (13)

Argenteuil, France
Bordeaux, France
Bordeaux, France
Garches, France
Levallois-Perret, France
Nantes, France
Nice, France
Paris, France
Paris, France
Paris, France
Paris, France
Paris, France
Tourcoing, France